Strategic Financial Concepts LLC Buys Shares of 88,757 Haleon plc (NYSE:HLN)

Strategic Financial Concepts LLC purchased a new position in shares of Haleon plc (NYSE:HLN) in the 4th quarter, Holdings Channel.com reports. The firm purchased 88,757 shares of the company’s stock, valued at approximately $847,000.

Several other hedge funds have also recently modified their holdings of the stock. Procyon Advisors LLC raised its position in Haleon by 41.3% during the 4th quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock worth $2,196,000 after buying an additional 67,329 shares during the last quarter. HighTower Advisors LLC boosted its holdings in Haleon by 27.2% in the 3rd quarter. HighTower Advisors LLC now owns 350,795 shares of the company’s stock valued at $3,701,000 after purchasing an additional 74,970 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Haleon by 1,689.4% in the 3rd quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock valued at $2,803,000 after buying an additional 250,169 shares during the period. Chartwell Investment Partners LLC boosted its stake in shares of Haleon by 107.8% in the third quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company’s stock valued at $5,030,000 after buying an additional 246,594 shares in the last quarter. Finally, Townsquare Capital LLC grew its stake in shares of Haleon by 29.8% during the 3rd quarter. Townsquare Capital LLC now owns 475,618 shares of the company’s stock worth $5,032,000 after purchasing an additional 109,217 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Performance

Shares of HLN opened at $9.98 on Wednesday. The company has a 50-day moving average of $9.55 and a two-hundred day moving average of $9.81. The stock has a market cap of $45.15 billion, a P/E ratio of 29.34, a PEG ratio of 2.70 and a beta of 0.28. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.